Journal
CURRENT OPINION IN PHARMACOLOGY
Volume 34, Issue -, Pages 112-118Publisher
ELSEVIER SCI LTD
DOI: 10.1016/j.coph.2017.09.006
Keywords
-
Categories
Funding
- association Vaincre La Mucoviscidose (Paris, France)
Ask authors/readers for more resources
Development of Cystic Fibrosis Transmembrane conductance Regulator (CFTR) modulators, targeting the root cause of cystic fibrosis (CF), represents a challenge in the era of personalized medicine, as CFTR mutations lead to a variety of phenotypes, which likely require different, specific treatments. CF drug development is also complicated by the need to preserve the right balance between stability and flexibility, required for optimal function of the CFTR protein. In this review, we highlight how structural data can be exploited in this context to understand the molecular mechanisms of disease-associated mutations, to characterize the mechanisms of action of known modulators and to rationalize the search for novel, specific compounds.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available